• Kelley Flesher, Sophia Pathan, and KofkeWilliam AndrewWADepartment of Neurology, Neurocritical Care Division, University of Pennsylvania, Philadelphia, PA..
• Department of Neurology, Neurocritical Care Division, University of Pennsylvania, Philadelphia, PA.
• J Neurosurg Anesthesiol. 2025 Jan 1; 37 (1): 4104-10.

AbstractMinimally invasive, image-guided endovascular procedures are becoming increasingly prevalent as techniques and technologies have advanced, particularly within the realm of neurovascular interventions. Endovascular approaches ubiquitously result in endothelial injury with subsequent risk of thromboembolic complications. Periprocedural antiplatelet agent use is an integral component of the management of patients undergoing endovascular neurointerventional procedures. This patient population has a unique risk profile encompassing thromboembolic and hemorrhagic complications simultaneously, and the precise balance of these risks impacts patient outcomes almost as much as the interventional procedure itself. Clinical experience and study consensus demonstrate overall improved outcomes with the use of periprocedural antiplatelet agents, though current practices remain highly institution and practitioner-dependent. This focused review will discuss the major mechanisms of action of antiplatelet agents, and their clinical indications and management in the periprocedural neurointerventional setting. Despite the importance of antiplatelet agents in the management of neurointerventional patients, many questions remain. Further research and clinical expertise are needed to establish standardized, procedure-specific, antiplatelet regimens as well as standardized monitoring of antiplatelet agent regimen efficacy and safety.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

11 keywords...

hide…